

Cover Story
This was not your ordinary ODAC, but a three-day checkpoint inhibitor marathon that consumed April 27, 28, and 29. You might call it six ODACs for the price of one: subtle as all get-out, if-you-blink-you-miss-it head-spinner of a shindig.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - Bhattacharya: New grant review criterion is “not political”
- With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shut down
- Population-based cancer surveillance is a national treasure at risk
- Ci4CC’s 24th Symposium & Workshop set to focus on precision oncology powered by data intelligence